CA2257841C - Medicinal aerosol formulations of formoterol - Google Patents
Medicinal aerosol formulations of formoterol Download PDFInfo
- Publication number
- CA2257841C CA2257841C CA002257841A CA2257841A CA2257841C CA 2257841 C CA2257841 C CA 2257841C CA 002257841 A CA002257841 A CA 002257841A CA 2257841 A CA2257841 A CA 2257841A CA 2257841 C CA2257841 C CA 2257841C
- Authority
- CA
- Canada
- Prior art keywords
- hfa
- ethanol
- formulation
- formoterol
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 238000009472 formulation Methods 0.000 title claims abstract description 95
- 239000000443 aerosol Substances 0.000 title claims abstract description 45
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 229960002848 formoterol Drugs 0.000 title claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 92
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims abstract description 44
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000004094 surface-active agent Substances 0.000 claims abstract description 19
- 239000007971 pharmaceutical suspension Substances 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003380 propellant Substances 0.000 claims description 42
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 35
- 229960000193 formoterol fumarate Drugs 0.000 claims description 35
- 239000004067 bulking agent Substances 0.000 claims description 26
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 15
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 15
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 15
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000005642 Oleic acid Substances 0.000 claims description 15
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 13
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229950010030 dl-alanine Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 33
- 229940079593 drug Drugs 0.000 abstract description 26
- 239000013078 crystal Substances 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 5
- 239000000725 suspension Substances 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003311 flocculating effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 239000008249 pharmaceutical aerosol Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- PPZSOILKWHVNNS-UHFFFAOYSA-N guaiacylglycerol-beta-guaiacyl ether Chemical compound COC1=CC=CC=C1OC(CO)C(O)C1=CC=C(O)C(OC)=C1 PPZSOILKWHVNNS-UHFFFAOYSA-N 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000001812 pycnometry Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9612297.3A GB9612297D0 (en) | 1996-06-11 | 1996-06-11 | Medicinal aerosol formulations |
| GB9612297.3 | 1996-06-11 | ||
| PCT/US1997/009471 WO1997047286A1 (en) | 1996-06-11 | 1997-06-02 | Medicinal aerosol formulations of formoterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2257841A1 CA2257841A1 (en) | 1997-12-18 |
| CA2257841C true CA2257841C (en) | 2008-05-20 |
Family
ID=10795182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002257841A Expired - Lifetime CA2257841C (en) | 1996-06-11 | 1997-06-02 | Medicinal aerosol formulations of formoterol |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1400239A1 (enExample) |
| JP (1) | JP5000793B2 (enExample) |
| AR (1) | AR009231A1 (enExample) |
| AT (1) | ATE275940T1 (enExample) |
| AU (1) | AU726382B2 (enExample) |
| CA (1) | CA2257841C (enExample) |
| DE (1) | DE69730723T2 (enExample) |
| DK (1) | DK0934057T3 (enExample) |
| ES (1) | ES2229366T3 (enExample) |
| GB (1) | GB9612297D0 (enExample) |
| ID (1) | ID19520A (enExample) |
| NO (1) | NO320403B1 (enExample) |
| NZ (1) | NZ333202A (enExample) |
| PT (1) | PT934057E (enExample) |
| WO (1) | WO1997047286A1 (enExample) |
| ZA (1) | ZA974546B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| ES2178479T3 (es) * | 1998-10-17 | 2002-12-16 | Boehringer Ingelheim Pharma | Concentrado de principio activo con formoterol, apto para el almacenamiento. |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| UA73986C2 (uk) | 2000-05-22 | 2005-10-17 | К'Єзі Фармачеутічі С.П.А. | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
| SE0004750D0 (sv) | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| ES2222294T3 (es) | 2001-07-02 | 2005-02-01 | Chiesi Farmaceutici S.P.A. | Formulacion optimizada de tobramicina para administracion en forma de aerosol. |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| GB0207899D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
| AU2003265639A1 (en) * | 2002-08-27 | 2004-03-19 | Schering Corporation | Process for producing metered dose inhaler formulations |
| CA2528479A1 (en) * | 2003-06-13 | 2004-12-23 | Altana Pharma Ag | Formoterol and ciclesonide combination |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| AU2004285447A1 (en) * | 2003-10-20 | 2005-05-12 | Schering Corporation | Pharmaceutical compositions |
| EP1925293A3 (en) * | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| ES2398480T3 (es) * | 2006-10-17 | 2013-03-19 | Lithera, Inc. | Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea |
| SMT202000077T1 (it) | 2009-05-29 | 2020-03-13 | Pearl Therapeutics Inc | Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| DK2482799T3 (da) * | 2009-10-02 | 2014-09-01 | Chiesi Farma Spa | Farmaceutiske aerosolformuleringer af formoterol og beclometasondipropionat |
| MX361286B (es) | 2013-03-15 | 2018-12-03 | Pearl Therapeutics Inc | Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508616A (ja) * | 1989-02-23 | 1993-12-02 | ローヌー プーラン ローラー インターナショナル（ホウルディングス）インコーポレイテッド | 治療用エアロゾル剤 |
| IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| GB9024365D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| WO1992022288A1 (en) * | 1991-06-10 | 1992-12-23 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| AU2178992A (en) * | 1991-06-10 | 1993-01-12 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| CA2125665C (en) * | 1991-12-12 | 2001-06-12 | Rachel Ann Akehurst | Medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| DK0617610T3 (da) * | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
| GB9207400D0 (en) * | 1992-04-02 | 1992-05-13 | Smithkline Beecham Plc | Novel use |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
-
1996
- 1996-06-11 GB GBGB9612297.3A patent/GB9612297D0/en active Pending
-
1997
- 1997-05-23 ZA ZA974546A patent/ZA974546B/xx unknown
- 1997-06-02 JP JP50165698A patent/JP5000793B2/ja not_active Expired - Lifetime
- 1997-06-02 NZ NZ333202A patent/NZ333202A/en not_active IP Right Cessation
- 1997-06-02 DE DE69730723T patent/DE69730723T2/de not_active Expired - Lifetime
- 1997-06-02 AT AT97929756T patent/ATE275940T1/de not_active IP Right Cessation
- 1997-06-02 DK DK97929756T patent/DK0934057T3/da active
- 1997-06-02 EP EP03014565A patent/EP1400239A1/en not_active Withdrawn
- 1997-06-02 AU AU33739/97A patent/AU726382B2/en not_active Expired
- 1997-06-02 PT PT97929756T patent/PT934057E/pt unknown
- 1997-06-02 EP EP97929756A patent/EP0934057B1/en not_active Expired - Lifetime
- 1997-06-02 WO PCT/US1997/009471 patent/WO1997047286A1/en not_active Ceased
- 1997-06-02 CA CA002257841A patent/CA2257841C/en not_active Expired - Lifetime
- 1997-06-02 ES ES97929756T patent/ES2229366T3/es not_active Expired - Lifetime
- 1997-06-04 AR ARP970102437A patent/AR009231A1/es unknown
- 1997-06-09 ID IDP971970A patent/ID19520A/id unknown
-
1998
- 1998-12-07 NO NO19985720A patent/NO320403B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ333202A (en) | 2000-06-23 |
| EP0934057A1 (en) | 1999-08-11 |
| JP5000793B2 (ja) | 2012-08-15 |
| PT934057E (pt) | 2004-12-31 |
| DE69730723T2 (de) | 2005-10-06 |
| ID19520A (id) | 1998-07-16 |
| EP0934057B1 (en) | 2004-09-15 |
| DK0934057T3 (da) | 2005-01-24 |
| AU3373997A (en) | 1998-01-07 |
| NO985720L (no) | 1999-02-11 |
| ZA974546B (en) | 1998-11-23 |
| NO320403B1 (no) | 2005-11-28 |
| GB9612297D0 (en) | 1996-08-14 |
| JP2000513340A (ja) | 2000-10-10 |
| CA2257841A1 (en) | 1997-12-18 |
| DE69730723D1 (de) | 2004-10-21 |
| ES2229366T3 (es) | 2005-04-16 |
| WO1997047286A1 (en) | 1997-12-18 |
| EP1400239A1 (en) | 2004-03-24 |
| NO985720D0 (no) | 1998-12-07 |
| ATE275940T1 (de) | 2004-10-15 |
| AR009231A1 (es) | 2000-04-12 |
| AU726382B2 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2257841C (en) | Medicinal aerosol formulations of formoterol | |
| US6054488A (en) | Medicinal aerosol formulations of formoterol | |
| JP4824267B2 (ja) | 医療用エアゾール配合物 | |
| CA2126244C (en) | Suspension aerosol formulations | |
| EP0932397B2 (en) | Medicinal aerosol formulations comprising budesonide | |
| US6039932A (en) | Medicinal inhalation aerosol formulations containing budesonide | |
| KR20010053025A (ko) | 가압 정량 흡입기 및 제약학적 분무 제제형 | |
| CZ194797A3 (en) | Pharmaceutical aerosol preparation, process of its preparation and use | |
| US7105152B1 (en) | Suspension aerosol formulations | |
| US20050207984A1 (en) | Formoterol and ciclesonide aerosol formulations | |
| SA97180339B1 (ar) | صياغات رش هوائي مومتيازون فيورات mometasone furoate خالية من كلوروفلوروكربون chlorofluorocarbon | |
| US7101534B1 (en) | Suspension aerosol formulations | |
| AU645366B2 (en) | Aerosol composition and a process preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170602 |